Ignite Creation Date:
2024-05-06 @ 2:40 PM
Last Modification Date:
2024-10-26 @ 1:35 PM
Study NCT ID:
NCT04396236
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2020-05-18
Brief Title:
A Study of Lasmiditan LY573144 Treatment in Children Aged 6 to 17 With Migraine
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Pediatric Options for Migraine Relief A Randomized Double-Blind Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine PIONEER-PEDS1
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PIONEER-PEDS1
Brief Summary:
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine The study will last up to 20 weeks and may include up to 4 visits
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H8H-MC-LAHV | OTHER | None | None |
| 2019-004378-24 | EUDRACT_NUMBER | Eli Lilly and Company | None |